Oncology

Clinical-stage developer of Eye90 microspheres, an yttrium-90 radioembolization device made from a glass composition that stays visible during the procedure. Indicated work targets benign and malignant hypervascular tumors, including liver cancer.

Redesigned MRI hardware for mobile cancer screening and runs the scanners itself as trailer-based imaging clinics billed per scan, starting with prostate imaging before biopsy.

Builds an MRI-compatible surgical robot that lets neurosurgeons place leads, take biopsies and ablate tumors while the patient is inside the scanner. It won a $2 million Phase II SBIR from the National Cancer Institute in September 2026.

Makes a portable cryoablation device that lets nurses and community health workers treat precancerous cervical cells at the point of care in primary care clinics.

A catheter with a microchip sensing array that detects individual nerve signals from inside a blood vessel, ablates the overactive ones and checks the result during the procedure. First clinical work is in pancreatic cancer pain.

Sells Clairity Breast, FDA-authorized software that estimates a woman's five-year breast cancer risk from an existing screening mammogram. Now also offered directly to patients through Everlywell.

Cleveland Diagnostics develops blood tests that read structural changes in cancer-related proteins. Its IsoPSA test helps urologists decide whether to biopsy men with elevated PSA.

Building SOMA-1, a coin-sized wireless implant that monitors electrical activity and delivers targeted stimulation as part of cancer treatment.

Runs the UroAmp platform, a urine-based tumor DNA test for non-muscle invasive bladder cancer, covering therapy response monitoring and post-treatment surveillance. Veracyte agreed to acquire the company in September 2026.

Cordance Medical is developing a focused ultrasound system that temporarily opens the blood-brain barrier for drug delivery and liquid biopsy in brain tumors.

Curadel Surgical Innovations develops near-infrared fluorescent contrast agents for image-guided surgery, led by ZW800-1 for visualizing the ureters during abdominal and pelvic procedures.

Builds robotically assisted radiation therapy systems for brachytherapy and intraoperative radiation therapy. Its Vektra platform follows Sculptura, a beam-sculpting system Empyrean bought from Sensus Healthcare in 2022.

Builds the Vanquish water vapor ablation system, which delivers thermal energy to prostate tissue through the urethra. Founded by Michael Hoey and named for his father, who died of prostate cancer.

Develops blood-based cancer screening tests built on cell-free DNA methylation and machine learning. SimpleScreen CRC is its first FDA-approved product; listed on Nasdaq as FRNM in July 2026.

Galvanize Therapeutics builds pulsed electric field ablation systems. Aliya is cleared for soft tissue ablation and is being studied in solid tumors; RheOx targets chronic bronchitis.

Sequencing-based cancer screening company. Its Galleri test reads cancer-specific methylation patterns in blood to flag signals from multiple cancer types and predict the tissue of origin.

Sells GammaTile, a bioresorbable brachytherapy implant placed in the resection cavity during brain tumor surgery. Cleared under 510(k) with product code KXK and used at more than 150 US cancer centers.

HistoSonics makes the Edison histotripsy system, which uses focused ultrasound to destroy liver tumors without incisions, heat or radiation.

Developing a genetically encoded biomaterial that plastic and reconstructive surgeons use to regenerate fat tissue. Spun out of work by Duke professor Ashutosh Chilkoti.

Builds devices that let patients manage parts of cancer treatment at home, including a wearable aimed at preventing chemotherapy hair loss.

Builds airway and GI stents, cryo biopsy probes and steerable endobronchial instruments, plus molecular diagnostics for lung cancer triage. Formed under Ajax Health in 2023 and acquired Thoracent in 2025.

Makes the Comfort Marker, a powered device that places permanent skin reference points on radiotherapy patients at a shallower depth than a hand held lancet. It entered the US market in September 2026.

Handheld imaging device using frequency domain near infrared spectroscopy to indicate within a week of starting treatment whether a breast cancer therapy is working.

Builds optical coherence tomography systems with AI detection for assessing surgical margins during cancer surgery. Listed on the TSX Venture Exchange as PINK.

Makes the Prana System, a single-use image-guided electrosurgical tool that combines CT-guided targeting with tissue excision. It was cleared in April 2026 to remove tissue and control bleeding.

Runs a single-cell functional test that exposes a patient's own tumor cells to a library of treatments to see which ones work. Targets hematological malignancies and solid tumors.

Makes a single-sided point-of-care MRI system for prostate procedures, cleared for MRI-guided prostate biopsy, with AI planning and robotic needle guidance still in development.

Builds Concentriq, a digital pathology software platform for diagnostic laboratories and biopharma. The Concentriq AP-Dx version is FDA cleared for primary diagnosis on scanned surgical pathology slides.

Software-only cancer imaging company that combines biophysical modeling and machine learning. Its products are TumorSight Viz, TumorSight RISK and the research tool PhenoScope.

Builds DERM, an AI tool that triages suspected skin cancer referrals from lesion images. It is used across NHS dermatology pathways in the UK.

Develops a high intensity focused ultrasound system for non invasive treatment of pancreatic cancer, with real time guidance, cavitation bubble visualization and robot assisted positioning.

Makes pressure-enabled infusion catheters for liver and pancreatic embolization procedures in interventional radiology. Its cleared devices include the TriNav Infusion System, TriNav Infusion System LV, TriNav Advance and a pancreatic retrograde venous infusion system.

Berlin AI company whose software reads screening mammograms inside Germany's national breast cancer screening program. In September 2026 it received CE certification for a Class IIb autonomous triage function that reports clearly normal exams without a radiologist.